Blockbuster Sanofi & Regeneron Drug Dupixent Notches FDA Nod for an Inflammatory Skin Disease

Sanofi and Regeneron Prescribed drugs drug Dupixent has received FDA approval for persistent spontaneous urticaria, introducing a brand new strategy to the remedy of this inflammatory pores and skin dysfunction. It’s the seventh FDA permitted indication for the blockbuster product.

The regulatory determination introduced Friday covers the remedy of sufferers age 12 and older whose persistent spontaneous urticaria (CSU) signs proceed regardless of remedy with standard-of-care antihistamines.

CSU is partly pushed by kind 2 irritation, a kind of overactive immune response. This response result in hives and itching; CSU is outlined as illness that lasts for greater than six weeks. Sanofi estimates 1.7 million individuals within the U.S. are affected by CSU. Regardless of the vast availability of antihistamines, the corporate says about half of CSU sufferers have illness that’s inadequately managed by these commonplace remedies.

Antihistamines goal H1 receptors, receptors on immune cells that play a job in immune response and irritation. The second-line remedy possibility for CSU is Genentech’s Xolair, an bronchial asthma drug that expanded its approval to the inflammatory pores and skin dysfunction in 2014. Xolair is an antibody designed to dam immunoglobulin E receptors, that are concerned in allergic reactions and immune responses. However different pathways play a job in CSU. Dupixent, a drug administered by injection each two weeks, is a monoclonal antibody designed to dam the signaling pathways IL-13 and IL-4.

Dupixent’s FDA approval in CSU relies on the outcomes of two Part 3 assessments that evaluated the drug as an add-on to antihistamines, in comparison with a placebo and antihistamines. Outcomes confirmed Dupixent met main and secondary targets of lowering itch severity and itch and hive exercise in comparison with the management arm at 24 weeks. The examine drug arm additionally confirmed elevated probability of well-controlled illness or a whole response at 24 weeks. On security, the outcomes have been in step with the recognized security profile of Dupixent in its permitted indications. The commonest hostile occasion reported was injection website reactions.

Dupixent was first permitted in 2017 as a remedy for atopic dermatitis. It’s Sanofi’s top-selling product, accounting for greater than €13 billion (about $14.7 billion) in income in 2024. Sanofi’s irritation and immunology technique contains increasing use of the drug to different indications. Final yr, the European Medicines Fee and the FDA permitted Dupixent for persistent obstructive pulmonary illness.

“This FDA approval supplies a brand new remedy possibility to assist handle the underlying drivers of those extreme and recurring indicators and signs,” Alyssa Johnsen, world therapeutic space head, immunology and oncology growth at Sanofi, mentioned in a ready assertion. “Dupixent has the potential to enhance outcomes for CSU sufferers who beforehand had restricted remedy choices.”

In 2023, the FDA turned down Sanofi’s preliminary utility for the drug in CSU, asking for extra medical information to indicate efficacy. That submission was based mostly on two Part 3 research, certainly one of which did not meet the principle trial purpose. The resubmission included information from a 3rd Part 3 check. Dupixent is permitted for CSU in Japan, the United Arab Emirates, and Brazil. The drug continues to be underneath assessment on this indication in Europe and different markets around the globe.

There are different corporations attempting to convey new approaches to the remedy of CSU. Celldex Therapeutics is in late-stage medical growth with barzovolimab, an antibody drug designed to bind to the KIT receptor on mast cells. Evommune goals to handle mast cell activation with an oral small molecule, EVO756. When the startup unveiled a $115 million Sequence C financing final October, it mentioned it anticipated preliminary Part 2b information in CSU within the first half of 2025.

However CSU drug analysis has additionally led to failures. In 2022, Third Harmonic discontinued growth of an oral small molecule KIT inhibitor after Part 1 information confirmed indicators of potential liver toxicity. The corporate turned its focus to a distinct KIT-blocking small molecule, THB335, which is presently being readied for Part 2 growth. However final week, Third Harmonic introduced plans to dissolve the corporate and promote its property, together with THB335, returning money to shareholders.

In the meantime, Allakos has twice fallen quick in its effort to develop antibodies that inhibit mast cells. Final yr, Allakos reported its drug lirentelimab didn’t beat a placebo in a Part 2 check in CSU. The biotech turned its focus to a distinct drug, AK006. However the Part 1 failure of that drug in January triggered the biotech’s second company restructuring previously yr.

Photograph: Getty Photos